...Kayla C. LaRue-Nolan; Glancis Luzeena Raja Arul; Ashley N. Sigafoos; Jiaqi Shi; Martin E. Fernandez-Zapico Pancreatic cancer is a malignancy arising from the endocrine or exocrine compartment of this organ. Tumors from exocrine origin comprise over 90% of all pancreatic cancers diagnosed...

... mechanism of Hh/GLI signaling pathway regulation in cancer cells. 21 8 2022 20 7 2023 21 7 2023 © 2023 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2023 BCL2 cell survival GLI1 pancreatic cancer SUFU Correspondence...

... transcriptional axis regulating the expression of SDF1, a major driver of cancer cell migration, involving the transcription factor GLI1 and histone acetyltransferase p300. We demonstrate that conditioned media from CAFs overexpressing GLI1 induce the migration of pancreatic cancer cells, and this effect...

... disease, to have an anticancer effect in pancreatic cancer via its role as an AhR agonist [ 29 ]. Additionally, based on the computer modeling and the enzymatic assay with a recombinant IDO1, we do know that carbidopa has a direct inhibitory effect on IDO1 activity. In the present study, we asked...

... a logical and viable therapeutic strategy. ascites fluid KPC metastasis pancreatic cancer SLC6A14 survival We have found SLC6A14 to be significantly up-regulated in PDAC [ 4 ]. SLC6A14, also known as ATB 0,+ , is an amino acid transporter (AAT) energized by three driving forces: a Na...

... collectively, these studies demonstrate a functional link between PEPT1 and extracellular protein breakdown in the tumor microenvironment as a key determinant of pancreatic cancer growth, thus identifying PEPT1 as a potential therapeutic target for PDAC. glibenclamide lactate MMPs pancreatic cancer...

..., carbidopa but not dopamine exhibited AhR activity in BxPC3 pancreatic cancer cells whereas minimal activity was observed for both compounds in Panc1 pancreatic cancer cells. In contrast with a previous report, the induction responses and cytotoxicity of carbidopa was observed only at high concentrations...

...Aimin Cai; Hailun Zheng; Zhiwei Chen; Xinlu Lin; Chen Li; Qing yao; Yangzom D. Bhutia; Vadivel Ganapathy; Ruijie Chen; Longfa Kou Gemcitabine is the first-line chemotherapy for pancreatic cancer. To overcome the often-acquired gemcitabine resistance, other drugs are used in combination...

..., and this compound inhibits pancreatic cancer cell and tumor growth. These results are consistent with activities of other AhR-active compounds that inhibit carcinogenesis. Like carbidopa, these chemicals are selective AhR modulators with potential clinical applications that are AhR-dependent. Correspondence...

...Jiro Ogura; Seiji Miyauchi; Kazumi Shimono; Shengping Yang; Sathisha Gonchigar; Vadivel Ganapathy; Yangzom D. Bhutia Carbidopa is used with l -DOPA ( l -3,4-dihydroxyphenylalanine) to treat Parkinson's disease (PD). PD patients exhibit lower incidence of most cancers including pancreatic cancer...

... 30 8 2011 5 9 2011 © The Authors Journal compilation © 2012 Biochemical Society 2012 chemoresistance fibrosis microRNA membrane-type 1 matrix metalloproteinase (MT1-MMP) pancreatic cancer Snail transforming growth factor-β (TGF-β) In the complex interplay between...

... unexplored. In the present study, we found that hHS6ST2 , but not other variants, was activated in human PC (pancreatic cancer). shRNA (short hairpin RNA)-mediated silencing of endogenous hHS6ST2 expression in the PC cell line PANC-1 inhibited cell invasion and migration. hHS6ST2 knockdown also resulted...

... -mediated cell growth, and that mechanistically some members of this subset accomplish this, at least in part, through regulation of the cyclin A promoter. cyclin A Krüppel-like factor 11 (KLF11) Krüppel-like factor (KLF) protein pancreatic cancer tumour suppression V-Ki-ras2 Kirsten rat sarcoma...